for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

66.42USD

Change

0.46(+0.70%)

Volume

9,775,357

Today's Range

65.89

 - 

67.02

52 Week Range

60.32

 - 

79.61

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
65.96
Open
65.89
Volume
9,775,357
3M AVG Volume
129.02
Today's High
67.02
Today's Low
65.89
52 Week High
79.61
52 Week Low
60.32
Shares Out (MIL)
1,266.46
Market Cap (MIL)
83,535.41
Forward P/E
9.41
Dividend (Yield %)
3.82

Next Event

Q3 2019 Gilead Sciences Inc Earnings Release

Latest Developments

More

FDA Warns Patients, Health Care Professionals About Rare Instances Of Serious Liver Injury In Some Patients With Advanced Liver Disease

Alberta Provides Access To Biktarvy For The Treatment Of Hiv

Assembly Biosciences Announces Appointment Of John Mchutchison As President And Chief Executive Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Robin L. Washington

Chief Financial Officer, Executive Vice President

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel

Jyoti Mehra

Executive Vice President of Human Resources

Andrew Dickinson

Executive Vice President - Corporate Development and Strategy

Key Stats

2.08 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

30.4K

2017

26.1K

2018

22.1K

2019(E)

22.3K
EPS (USD)

2016

11.570

2017

8.840

2018

6.670

2019(E)

7.008
Price To Earnings (TTM)
14.25
Price To Sales (TTM)
3.74
Price To Book (MRQ)
3.70
Price To Cash Flow (TTM)
11.32
Total Debt To Equity (MRQ)
115.33
LT Debt To Equity (MRQ)
106.49
Return on Investment (TTM)
10.98
Return on Equity (TTM)
9.27

Latest News

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

UPDATE 2-GSK's long acting HIV injection gets boost from study

* GSK up against competition from Gilead's 3-drug combo (Releads, adds background on rivalry with Gilead)

Medicare to cover expensive cancer cell therapies

The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc <GILD.O> and Novartis AG <NOVN.S>.

Patient groups push back against Gilead's pricey HIV prevention treatment

Gilead Sciences Inc <GILD.O> hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.

FDA panel backs Gilead's HIV prevention drug Descovy, except in women

An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

FDA panel backs Gilead's HIV prevention drug for certain population

Independent experts on an FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

FOCUS-Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments

Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG, new data shows, helping explain why sales of the two products have not met rosy expectations.

Gilead results beat Street estimates as demand grows for HIV drug

Gilead Sciences Inc <GILD.O> beat Wall Street estimates for second-quarter revenue and profit on Tuesday, driven by higher sales of HIV treatments, and the U.S. drugmaker raised its full-year sales forecast.

Gilead quarterly profit rises 3.5%

Gilead Sciences Inc reported a 3.5% rise in quarterly profit on Tuesday, as higher sales of its HIV drugs cushioned sluggish demand for its flagship hepatitis C treatments.

BRIEF-Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis

* GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS

GSK's two-drug HIV Dovato treatment meets main goal in study

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

CORRECTED-UPDATE 1-GSK's Dovato suppresses AIDS virus at same levels of 3-drug regimen (July 10)

GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>, news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences <GILD.O> will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV <GLPG.AS>.

Pharma firm Gilead to raise Galapagos stake in $5.1 bln deal -report

Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.

Appeals court mulls reviving Merck's $2.54 billion patent win against Gilead

A federal appeals court on Tuesday was considering whether to reinstate a $2.54 billion jury verdict Merck & Co Inc won against Gilead Sciences Inc in a dispute over hepatitis C treatments — the largest ever in a patent infringement case.

Gilead to separate Kite cell therapy unit, posts higher profit

Gilead Sciences Inc, which hired Roche veteran Daniel O'Day to be its new chief executive, on Thursday said Kite Pharma, the cancer-focused cell therapy company it acquired in 2017, will become a separate business unit.

Gilead posts higher first-quarter profit; drug sales in line with expectations

Gilead Sciences Inc on Thursday reported a higher first-quarter profit as sales of its important HIV and hepatitis C drugs were largely in line with Wall Street estimates.

Gilead experimental NASH drug fails another study

Gilead Sciences Inc's experimental drug aimed at treating a type of fatty liver disease known as NASH failed to meet the main goal of a late-stage study on Thursday, two months after it failed another trial.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up